Download PDF
CC BY-NC-ND 4.0 · World J Nucl Med 2012; 11(03): 110-116
DOI: 10.4103/1450-1147.103409
Original Article

Standard Operating Procedure for Prospective Individualised Dosimetry for [131] I-rituximab Radioimmunotherapy of Non-Hodgkin′s Lymphoma

Phillipe Calais
Department of Nuclear Medicine, The University of Western Australia, Fremantle Hospital, Fremantle WA, Australia
,
J. Turner
Department of Nuclear Medicine, The University of Western Australia, Fremantle Hospital, Fremantle WA, Australia
› Author Affiliations
› Further Information
  PDF Download Permissions and Reprints

Radioimmunotherapy (RIT) is an attractive therapy for non-Hodgkin′s lymphoma (NHL) as it allows targeted tumor irradiation which provides a cytotoxic effect significantly greater than that of the immune-mediated effects of a non-radioactive, or ′cold′, antibody alone. Anti-CD20 antibodies such as rituximab are ideal for RIT, as not only is it easily iodinated, but the CD20 antigen is found on more than 95% of B-cell NHL. A standard operating procedure (SOP) has been formulated for personalized prospective dosimetry for safe, effective outpatient 131 I-rituximab RIT of NHL. Over five years, experience of treatment of outpatients with 131 I-rituximab was analyzed with respect to critical organ radiation dose in patients and radiation exposure of their carers. This radiation safety methodology has been refined; and offers the potential for safe, practical application to outpatient 131 I-rituximab RIT of lymphoma in general and in developing countries in particular. Given endorsement and sanction of this SOP by local regulatory authorities the personalized dosimetry paradigm will facilitate incorporation of RIT into the routine clinical practice of therapeutic nuclear oncology worldwide.

Keywords

Dosimetry - I-131 rituximab - non-Hodgkin′s lymphoma - standard operating procedure


Publication History

Article published online:
21 May 2022

© 2012. Sociedade Brasileira de Neurocirurgia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India